AUTHORS
Sodiomon B. Sirima, Alphonse Ouedraogo, Nouhoun Barry, Mohamadou Siribie, Alfred B. Tiono, Issa Nébié, Amadou T. Konaté, Gloria Damoaliga Berges, Amidou Diarra, Moussa Ouedraogo, Issiaka Soulama, Alimatou Hema, Shrimati Datta, Yuanyuan Liang, Elizabeth T. Rotrosen, J. Kathleen Tracy, Leslie P. Jamka, Kathleen M. Neuzil, Matthew B. Laurens
ABSTRACT
Objectives: The World Health Organization pre-qualified single-dose typhoid conjugate vaccine (TCV) and requested data on co-administration with routine vaccines. We tested co-administration of Typbar TCV® [Bharat Biotech International] with routine group A meningococcal conjugate vaccine (MCV-A) and measles-rubella (MR) vaccine.
Methods: We conducted a double-blind, randomized, controlled trial in Ouagadougou, Burkina Faso. Children recruited at 15-month vaccination visits were randomly assigned (1:1:1) to receive: Group 1) TCV plus control vaccine (inactivated polio vaccine) and MCV-A 28 days later; Group 2) TCV and MCV-A; or, Group 3) MCV-A and control vaccine. Routine MR vaccine was administered to all participants. Safety was assessed at 0, 3, and 7 days after immunization; and unsolicited adverse events and serious adverse events for 28 days and 6 months after immunization, respectively.
Results: We recruited and vaccinated 150 children. Solicited symptoms were infrequent and similar for TCV and control recipients, as were adverse events (Group 1: 61.2%, Group 2: 64.0%, Group 3: 68.6%) and serious adverse events (Group 1: 2.0%, Group 2: 8.0%, Group 3: 5.9%). TCV generated robust immunity without interference with MCV-A vaccine.
Conclusions: TCV can be safely co-administered at 15 months with MCV-A without interference. This first study on co-administration of TCV with MCV-A provides data to support large-scale uptake in sub-Saharan Africa.
Click here to read the article, published in the International Journal of Infectious Diseases.
